๐ง
Neuroscience
Drug development for neurological and psychiatric disorders including Alzheimer's, Parkinson's, depression, and rare neurological conditions.
Companies
0
Pipeline Drugs
179
Key People
324
Neuroscience Pipeline (179 drugs)
Commercial: 41Approved: 31Phase 3: 18Phase 2: 15Pre-clinical: 15Phase 1: 12Preclinical: 10Approved/Commercial: 7Phase 1/2: 5Various: 2Regulatory: 2Phase (Early Clinical): 2Commercial/Approved: 2Discovery: 2Lead Optimization: 2Phase 2/3: 1Acquisition: 1Phase 1/2a: 1Phase 1b/2a: 1Emergency Use Authorization (Past): 1Phase 1b: 1Advanced Development: 1Early Discovery: 1Preclinical Research: 1Preclinical/Translational: 1Clinical Research: 1Research: 1All Phases: 1
Key People in Neuroscience
DA
David A. Ricks
Chairman and Chief Executive Officer
Eli Lilly
AA
Anat Ashkenazi
Executive Vice President and Chief Financial Officer
Eli Lilly
DM
Daniel M. Skovronsky
Chief Scientific and Medical Officer, President of Lilly Research Laboratories
Eli Lilly
AE
Anne E. White
Executive Vice President and President of Lilly International
Eli Lilly
PJ
Patrik Jonsson
Executive Vice President, President of Lilly USA
Eli Lilly
IY
Ilya Yuffa
Executive Vice President and President of Lilly Manufacturing Operations
Eli Lilly
CS
Christi Shaw
Executive Vice President and President of Lilly Oncology
Eli Lilly
MM
Mike Mason
Executive Vice President and President of Lilly Diabetes
Eli Lilly
RG
Ruth Gimmi
Executive Vice President, Chief Information and Digital Officer
Eli Lilly
MB
Melissa Barnes
Executive Vice President, Global Quality
Eli Lilly
GC
Giovanni Caforio, M.D.
Board Chair
Novartis
SM
Simon Moroney, D.Phil.
Vice-Chair
Novartis
NC
Nancy C. Andrews, M.D., Ph.D.
Board Member
Novartis
TB
Ton Buechner
Board Member
Novartis
PB
Patrice Bula
Lead Independent Director
Novartis